Xiuzheng Pharmaceutical Group Aims For A-Share Listing
This article was originally published in PharmAsia News
Executive Summary
Xiuzheng Pharmaceutical Group plans to go for A-share listing at the end of this year or early 2009, according to the company's president. As a TCM enterprise, Xiuzheng ranks among China's top 10 pharmaceutical corporations with its revenue of 5.7 billion yuan in 2007. The company will begin constructing its biomedical industry park with 1 billion yuan. With the biomedical industry its second largest core business, it aims to create value in the capital market for investors. An analyst notes that going public is inevitable for Xiuzheng, but whether it is the right move at a time when China's stock market is slowing down remains to be seen. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.